Crawford “review”
This article was originally published in The Tan Sheet
Executive Summary
The HHS Office of the Inspector General is "reviewing the circumstances" surrounding the resignation of FDA Commissioner Lester Crawford in response to requests from members of Congress, IG Daniel Levinson confirmed in a recent letter to Rep. Maurice Hinchey (D-N.Y.) and colleagues. "Depending upon the results of the review, we will determine the next appropriate action," Levinson said. According to OIG staff, the review currently is not a formal investigation. Lawmakers called for the investigation in September (1"The Tan Sheet," Oct. 3, 2005, p. 4)...
You may also be interested in...
Hinchey presses FDA
Rep. Maurice Hinchey (D-N.Y.) will use an upcoming hearing on FDA's budget request to pose questions about conflicts of interest to Acting Commissioner Andrew von Eschenbach, Hinchey's office says. Von Eschenbach is scheduled to discuss FDA's budget request for fiscal 2007 at a Feb. 16 hearing held by the Appropriations Subcommittee on Agriculture, Rural Development, FDA & Related Agencies. Hinchey says his questions will center on "von Eschenbach's own conflict as NCI Director," FDA's recently restated policy of preemption and the agency's "cozy relationship" with the drug industry. The congressman has campaigned to prevent scientists and doctors with conflicts of interest from participating on FDA committees. In September, he requested that the HHS Office of the Inspector General review the resignation of former FDA Commissioner Lester Crawford (1"The Tan Sheet" Oct. 31, 2005, In Brief)...
FDA Works To Stay Focused As Its Heads Spin; Deputies In Spotlight
A key challenge for FDA following the resignation of Commissioner Lester Crawford will be overcoming the impression that being without a permanent leader yet again will result in a period of stasis at the agency
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.